

Investor News

Markus Georgi
Senior Vice President
Investor Relations

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2485
F +49 6172 608-2488
markus.georgi@fresenius.com
www.fresenius.com

February 22, 2016

Fresenius Helios acquires hospital in North Rhine-Westphalia with more than 500 beds

Fresenius Helios acquires the municipal hospital in Velbert located in the German state of North Rhine-Westphalia. The hospital has 519 beds and, with approximately 1,000 employees, treats 45,000 patients each year, including 20,000 inpatients. Sales were approximately €67 million in 2014.

Fresenius Helios will fully own the hospital. Following the acquisition, it plans to invest in a new, state-of-the-art hospital building. The facility is an excellent fit with the company's existing presence and activities in North Rhine-Westphalia.

The acquisition is subject to approval by the German antitrust authorities. The parties agreed not to disclose the purchase price. The transaction is expected to close in the second quarter of 2016, and the hospital will already be accretive to Fresenius Group earnings starting this year.

#

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2014, Group sales were €23.2 billion. On September 30, 2015, the Fresenius Group had 220,853 employees worldwide.

For more information visit the Company's website at www.fresenius.com.
Follow us on Twitter: [www.twitter.com/fresenius_ir](https://twitter.com/fresenius_ir).

Fresenius Helios operates 87 acute care hospitals, including 7 maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden, and Wuppertal, as well as 24

post-acute care clinics. The Group has more than 34,000 beds and treats over 4.5 million patients – including more than 1.2 million inpatients – each year.

Fresenius Helios is a subsidiary of Fresenius SE & Co. KGaA.

For more information visit the company's website at www.helios-kliniken.de.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Dr. Ulf M. Schneider (Chairman), Dr. Francesco De Meo, Dr. Jürgen Götz,
Mats Henriksson, Rice Powell, Stephan Sturm, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick